The Dry Powder Inhaler Market is poised for significant growth, with a market value of USD 20.83 billion in 2024, projected to climb to USD 29.95 billion by 2034, representing a steady CAGR of 3.70% ...
Dublin, June 04, 2024 (GLOBE NEWSWIRE) -- The "Dry Powder Inhaler Global Market Report 2024" has been added to ResearchAndMarkets.com's offering. The dry powder inhaler market size has grown strongly ...
There are various kinds of inhalers present in the market that help one to control asthma. However, each comes with its own pros and cons. If you or your loved one suffers from asthma, you know that ...
The "Dry Powder Inhalers: Products, Therapeutics, Players and Forecasts" report has been added to Research and Markets' offering. The study is designed to provide drug company decision makers, drug ...
The dry powder inhaler market is projected to be worth USD 20.83 billion in 2024. The market is likely to reach USD 29.95 billion by 2034. The Industry is expected to surge at a CAGR of 3.70% from ...
Dry-powder inhalers (DPIs) are complex multifaceted systems designed to reproducibly deliver an efficacious dose of medicine in an appropriate, aerodynamic range of sizes to enable the treatment of ...
According to Future Market Insights, the global Dry Powder Inhaler Market is slated to exhibit a CAGR of nearly 4.6% during the forecast period (2021-2031), in terms of volume. Over 4000,000 Mn units ...
Researchers in the United Kingdom compared the potential impact on carbon footprint and asthma symptom control of switching maintenance therapy to a dry powder inhaler vs continuing with a metered ...
Asthma patients using dry powder inhalers are more likely to adherence to inhaled corticosteroid therapy than those using metered-dose inhalers, a new study has shown. Researchers studied 270 adults ...
Advances in drug formulation and inhalation device design are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods. Much of the interest in ...
The pros and cons to using a dry powder inhaler as treatment for chronic obstructive pulmonary disease. Neil Minkoff, MD: Dr Drummond, we’ve talked a little bit about the differences. You brought some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback